{
    "nctId": "NCT03437083",
    "briefTitle": "A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants",
    "officialTitle": "A Nationwide, Multi-institutional Retrospective Study of Efficacy and Safety of Eribulin in Korean Breast Cancer Patients",
    "overallStatus": "COMPLETED",
    "conditions": "Locally Advanced or Metastatic Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 340,
    "primaryOutcomeMeasure": "Progression-free survival (PFS) rate at 6 months",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Confirmed diagnosis of locally advanced or metastatic breast cancer\n* Participants who were treated with Eribulin between 01 June, 2014 and 31 December, 2016\n\nExclusion Criteria:\n\n* Not applicable",
    "sex": "ALL",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}